Summary
The AI response discusses generic-entry timing and DrugPatentWatch.com usage, which is not information contained in the provided JYNARQUE FDA label. It also omits key on-label elements requested in an FDA label alignment context (e.g., indication, dosing/administration, contraindications, boxed warning monitoring specifics, REMS requirements). As a result, there is no verifiable alignment to the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
There is no true generic version of Jynarque that can be dated to a specific public 'go generic' day in the information provided here.
The provided prescribing information does not discuss generic availability, generic approval/entry dates, or public 'go generic' days; therefore this statement cannot be supported or verified against the supplied label.
Jynarque is branded to treat specific conditions related to autosomal dominant polycystic kidney disease (ADPKD).
While the label includes an indication for slowing kidney function decline in adults at risk of rapidly progressing ADPKD, this statement is an imprecise restatement and does not match the label wording/population (adults at risk of rapidly progressing ADPKD). It is not clearly supported as written.
Patent and exclusivity status are typically tracked through drug patent databases rather than through a single, universal release date.
Not addressed in the provided prescribing information.
To determine the earliest realistic date a generic could enter, patent expiration dates listed for Jynarque/tolvaptan are normally checked.
Not addressed in the provided prescribing information.
To determine the earliest realistic date a generic could enter, regulatory exclusivities that may extend entry are normally checked.
Not addressed in the provided prescribing information.
To determine the earliest realistic date a generic could enter, litigation or 'skinny label'/ANDA timing factors are normally checked.
Not addressed in the provided prescribing information.
DrugPatentWatch.com tracks patent and exclusivity timelines for drugs.
Not addressed in the provided prescribing information.
DrugPatentWatch.com is often used to estimate when generics may enter.
Not addressed in the provided prescribing information.
To pin down an exact date, the first ANDA approval date (U.S.) for tolvaptan tied to Jynarque is relevant.
Not addressed in the provided prescribing information.
To pin down an exact date, the first market availability date after approval is relevant.
Not addressed in the provided prescribing information.
Whether the product is a full generic or only an alternative formulation can change how people describe 'generic'.
Not addressed in the provided prescribing information.
Contradictions
Important Omissions
Boxed warning content regarding serious/potentially fatal liver injury, including REMS restricted distribution and ALT/AST/bilirubin monitoring schedule.
Importance:
High
FDA-labeled indication wording (slow kidney function decline in adults at risk of rapidly progressing ADPKD).
Importance:
Moderate
FDA-labeled dosage and titration approach (initial 60 mg/day regimen; titration to 60 mg + 30 mg then to 90 mg + 30 mg with at least weekly intervals; down-titration based on tolerability; hydration encouragement).
Importance:
High
Key contraindications (e.g., significant liver impairment/injury; strong CYP3A inhibitors; uncorrected abnormal sodium; inability to sense/respond to thirst; hypovolemia; hypersensitivity; uncorrected urinary outflow obstruction; anuria).
Importance:
High
REMS requirements (prescriber certification, patient enrollment/compliance with monitoring, pharmacy certification/dispensing only to authorized patients).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response does not address label-required liver risk communication/monitoring, REMS restrictions, contraindications, or dosing. While it does not make a direct dosing/contraindication claim that contradicts the label, its failure to include critical on-label safety information is material in an FDA label alignment context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The statements are primarily about generic entry timing and external database use, which are not supported by the provided FDA label, and the response omits multiple material label safety requirements (boxed warning, monitoring schedule, REMS, contraindications, and dosing).
Suggested Improvement
Audit and report only claims supported by the provided prescribing information; include (with exact label-supported details) the boxed warning liver injury risk, required ALT/AST/bilirubin monitoring intervals, REMS restricted distribution requirements, labeled indication, contraindications, and labeled dosing/titration regimen.